Gather your GLP-1 vial, insulin syringe, alcohol swabs, and sharps container
The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy
Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
Ozempic should NOT be used if you have: A personal or family history of medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A history of pancreatitis Severe kidney problems Ozempic is linked to risks of pancreatitis, kidney problems and potential thyroid tumors (specifically medullary thyroid carcinoma)
Association between ultra-processed food consumption and mortality among U.S
Sofwave uses ultrasound technology to target the deeper layers of the skin, specifically the mid-dermis, to stimulate collagen production
